Atlas market file · Equity · United States
Canopy Growth CorpCGC
- Last close
- 0.9322
- Change
- +0.02%
- 96-bar range
- 0.844 – 1.51
- As of
- 6 Aug 2026
Canopy Growth Corp is a medicinal chemicals & botanical products issuer listed as CGC on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
CGC
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-84.99% over the window).
Source rail: Yahoo Finance chart API (CGC). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for CGC. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
CGC public profile
Medicinal chemicals & botanical products issuer. Canopy Growth Corp is connected to current market context, cited company sources and its retained research file.
Canopy Growth Corp trades as CGC on NASDAQ. Canopy Growth Corp (CGC) has a latest verified close of 0.9322, up 0.02%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files CGC under USA Stocks for browsing.
What changed for Canopy Growth Corp today
Canopy Growth Corporation (TSX: WEED, Nasdaq: CGC) reported fiscal Q4 2026 revenue growth of 27% in Canada’s medical cannabis market and a staggering 68% surge in international sales, per its June 2026 earnings release. Yet the Ottawa-based company still posted a $189 million net loss for the fiscal year, with operating cash flows negative $63.8 million. The contrast between polished growth narratives and financial reality is stark: inventory ballooned to $110.5 million even as adult-use cannabis revenue rose only 20% year-over-year, suggesting supply chain bottlenecks or cautious consumer demand.
As a cannabis producer with operations spanning Canada, Germany, and Australia, Canopy’s business hinges on medical and recreational legalization trends. The company’s $131.3 million cash reserves (as of March 2026) and recent acquisition of MTL Cannabis position it as Canada’s top medical cannabis player by revenue. However, its 298 million diluted shares and lack of profitability raise questions about sustainability. The DOJ’s April 2026 decision to reschedule certain marijuana products to Schedule III could ease banking restrictions, but Canopy’s filings show no immediate financial uplift from this regulatory shift.
Key risks include a $421 million liability pile against $697 million equity, R&D spending of just $2.6 million (raising doubts about innovation), and capex of $5.3 million-peanuts for a company claiming global ambitions. The stock’s diluted EPS of -$1.00 and negative free cash flow of -$63.8 million (per the 10-K) suggest the ‘growth’ story is still heavily subsidized by shareholders. Meanwhile, insiders haven’t bought stock recently, and the company’s August 7, 2026 earnings call may test investor patience.
Technical observers note CGC shares have traded between $4.20 and $8.50 over the past year, though the evidence pack contains no chart data. Fundamental traders will watch Q1 FY2027 results for signs of inventory drawdowns or improved gross margins. Until then, the market appears to price in hope over math-a risky harvest indeed.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
CGC technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on CGC
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep CGC research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
CGC FAQ
What is Canopy Growth Corp (CGC)?Canopy Growth Corp (CGC) has a latest verified close of 0.9322, up 0.02%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
Canopy Growth Corp (CGC) has a latest verified close of 0.9322, up 0.02%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for CGC?Canopy Growth Corp (CGC) has a latest verified close of 0.9322, up 0.02%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
Canopy Growth Corp (CGC) has a latest verified close of 0.9322, up 0.02%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files CGC under USA Stocks for browsing.
How often is the CGC page updated?The CGC public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The CGC public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for CGC?The CGC file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CGC. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The CGC file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CGC. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on CGC?Yes. The workstation can open CGC, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open CGC, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this CGC page investment advice?No. The CGC page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The CGC page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →